MedTrace Logo

Study to Investigate the Safety and Tolerability of AZD8848 in Butyrylcholinesterase Deficient Subjects

NCT01205867 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2015-08-14

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety and tolerability of AZD8848 in Butyrylcholinesterase deficient subjects in comparison with sex and age matched control subjects.

Conditions

  • Butyrylcholinesterase Deficiency

Interventions

DRUG

AZD8848

Nasal spray solution, intranasal, single ascending doses, 1.4 - 60 μg

Sponsors & Collaborators

Principal Investigators

  • Jesper Sonne, MD · DanTrials ApS, Copenhagen, Denmark

  • Sam Lindgren, MD, PhD · AstraZeneca R&D, Lund, Sweden

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2011-02-28
Completion
2012-01-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01205867 on ClinicalTrials.gov